LI-37 (Cathelicidin) – 5mg

LI-37

Product is sold for prescriber purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.

LI-37 is a synthetic peptide derived from the naturally occurring human cathelicidin antimicrobial peptide, LL-37. It belongs to a family of host defense peptides known for their broad-spectrum antimicrobial properties, immunomodulatory activity, and wound-healing potential. In preclinical studies using lab rats, LI-37 has shown promise as a therapeutic agent in treating infections and inflammatory conditions due to its unique ability to modulate immune responses while preserving tissue integrity.

A study by Zhang et al. (2020) demonstrated that LI-37 significantly reduced bacterial load and inflammation in a rat model of methicillin-resistant Staphylococcus aureus (MRSA) skin infection. Treatment with LI-37 enhanced bacterial clearance and promoted faster wound healing compared to control groups, suggesting its potential as an alternative to traditional antibiotics (PMID: 32019965).

Another study by Lyu et al. (2019) explored the peptide’s effects in a lipopolysaccharide (LPS)-induced lung injury model. LI-37 administration attenuated inflammation and reduced oxidative stress markers in rat lung tissues. The findings indicated that LI-37 modulated the expression of cytokines such as TNF-α and IL-6, thus limiting the extent of tissue damage (PMID: 31669328).

Lastly, research by Jiang et al. (2021) evaluated LI-37 in a chemically-induced colitis model. The peptide significantly improved colon morphology, reduced pro-inflammatory cytokines, and increased the expression of tight junction proteins, indicating enhanced barrier protection in the gastrointestinal tract (PMID: 34125549).

In conclusion, LI-37 exhibits antimicrobial, anti-inflammatory, and tissue-repair properties in rat models. These findings support its potential use in treating infections and inflammatory disorders, warranting further investigation in human clinical studies.